CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 662 enrolled
Drug / intervention
Adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01387815
NCT01387815N/ACompleted
CompareCT.gov

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

AbbVie (prior sponsor, Abbott)·observational·Posted Jul 6, 2011·Updated Dec 5, 2019

In Brief

An observational study evaluating Adalimumab for Psoriasis. Completed, enrolled 662 participants across 36 sites.

Detailed Summary

This was a Canadian post-marketing observational study (PMOS) utilizing a prospective cohort design that compared the real - life effectiveness of adalimumab to topical and traditional systemic agents in the management of psoriasis and its impact on the patient's quality of life and societal burden of illness.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada
CollaboratorsCato Research, JSS Medical Research Inc.

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 6, 2011
Enrollment StartAug 16, 2011
Primary CompletionJun 29, 2018
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 15.0 years ago

Interventions

Adalimumabbiological

Adalimumab administered by subcutaneous injection.